ISRCTN47137942已完成不适用
A double-blind, randomised parallel group study to compare the efficacy and safety of cefuroxime plus erythromycin in the treatment of patients with community-acquired pneumonia
HS R&D Regional Programme Register - Department of Health (UK)0 个研究点目标入组 0 人开始时间: 2004年1月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Not provided at time of registration
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a 54 week blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg in type 2 diabetic patients with insufficient glycaemic control on diet and exercisetype 2 diabetes mellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-008127-15-LVBoehringer Ingelheim RCV Gmbh1,811
进行中（未招募）
1 期
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg for up to 54 weeks in type 2 diabetic patients with insufficient glycaemic control on diet and exerciseEUCTR2008-008127-15-GBBoehringer Ingelheim Limited1,800
进行中（未招募）
不适用
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg for up to 54 weeks in type 2 diabetic patients with insufficient glycaemic control on diet and exercisetype 2 diabetes mellitusMedDRA version: 15.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-008127-15-EEBoehringer Ingelheim RCV Gmbh1,811
进行中（未招募）
不适用
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a 54 week blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg in type 2 diabetic patients with insufficient glycaemic control on diet and exerciseEUCTR2008-008127-15-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,800
尚未招募
4 期
A randomised, double blind, parallel-group study of the oxidative stress lowering effect of simvastatin and atorvastatin.arteriosclerosis1001108210003216AtherosclerosisNL-OMON30464Vrije Universiteit Medisch Centrum60